Chronic kidney disease (CKD) is defined as presence of kidney damage or decreased kidney function (estimated glomerular filtration rate \<60 mL/min/1.73 m^2^) for 3 or more months, irrespective of cause. Prevalence and incidence of CKD continues to increase globally. Secondary hyperparathyroidism (SHPT) and anemia are the principal and most commonly seen complications in patients with CKD, and especially affect patients receiving hemodialysis (HD) \[[@ref1]\]. Causes of SHPT include phosphate retention, decreased free calcium concentration, decreased 1,25-dihydroxyvitamin D (calcitriol) concentration, and increased fibroblast growth factor 23 concentrations, with reduced expression of vitamin D receptors, calcium-sensing receptors, fibroblast growth factor receptors, and klotho in the parathyroid glands. Most observational studies have reported associations between elevated parathyroid hormone (PTH) level and mortality \[[@ref2]--[@ref4]\]. Kidney Disease: Improving Global Outcomes guidelines suggest maintaining serum PTH value in HD patients in the range of 2 to 9 times upper reference limit for the assay due to technical differences in the laboratory \[[@ref5]\].

Mechanism underlying anemia in patients on maintenance HD is attributed to several factors, including decreased erythropoietin (EPO) production, hyporesponsiveness to EPO, low iron stores, multiple instances of blood sampling, gastrointestinal bleeding, dietary restrictions, decreased intestinal absorption due to phosphate medication, dialysis inadequacy, SHPT, and chronic inflammation \[[@ref6]--[@ref8]\]. Among these, EPO deficiency is considered the most important cause. PTH acts directly or indirectly to increase intracellular calcium concentrations, and this leads to critical conclusions, including anemia, immune dysfunction, neurotoxicity, and impairment of vascular reactivity. At the same time, HD patients with SHPT suffer from excessive oxidative stress and inflammation \[[@ref9], [@ref10]\].

Neutrophil gelatinase-associated lipocalin (NGAL) is small 25 kDa glycoprotein, a member of lipocalin superfamily that is rapidly released from cells such as renal tubules, liver hepatocytes, endothelial, and smooth muscle cells in response to inflammation and ischemia \[[@ref11], [@ref12]\]. NGAL, identified as component of neutrophil granules, inhibits bacterial growth by depleting their intracellular iron stores. NGAL has also been shown to induce apoptosis of primary bone marrow cells, including erythroid progenitor cells, and to inhibit erythroid cell production, leading to anemia \[[@ref13], [@ref14]\]. Previous study demonstrated relationship between iron deficiency anemia and serum NGAL level in chronic HD patients \[[@ref15]\]. The aim of present study was to test hypothesis whether NGAL might be correlated with severity of SHPT and anemia without iron deficiency.

MATERIALS AND METHODS {#sec1-2}
=====================

Patients {#sec2-1}
--------

Study was conducted with 61 chronic HD patients (mean age: 52.21±11.6 years; male/female: 29/32). All patients were anuric and were undergoing standard bicarbonate dialysis using standard biocompatible HD membrane 3 times a week for about 4 hours each session in the hemodialysis unit of Firat University. Blood flow rates were 250 to 300 mL/min and dialysate flow rates were 500 mL/min. Ultrafiltration varied according to the patients' actual weight. None had received intravenous iron or red cell blood transfusion in previous 2 months. Exclusion criteria of the study were as follows: patients who had been receiving HD for less than 6 months; age \<18 or \>70 years; serum PTH level \<150 pg/mL; presence of malignancy; presence or recent history of bleeding; B~12~ or folic-acid deficiency; iron deficiency anemia (transferring saturation value \<20% and/or serum ferritin level \<200 ng/mL); hemoglobinopathies; hemolytic anemias; liver, thyroid, or infectious disease; treatment with immunosuppressive drugs; and unwillingness to participate in the study. Causes of renal failure among HD patients were diabetic nephropathy in 25 (41%) patients, hypertension in 20 (32.8%), chronic glomerulonephritis in 4 (6.6%), polycystic kidney disease in 3 (4.9%), other cause in 4 (6.6%), and unknown cause in 5 (8.1%) patients. Mean duration of HD was 30.36±15.70 months (range: 6--68 months). Only 3 patients had permanent central venous catheters and the remainder (n=58) had arteriovenous fistula. Although there is no precise cut-off level determining risk groups, as shown in the Dialysis Outcomes and Practice Patterns Study \[[@ref10]\], patients with PTH over 600 have high risk of mortality; therefore, patients were divided into 3 groups based on PTH level: Group 1=150\<PTH≤300 pg/mL, Group 2=301≤PTH≤600 pg/mL, and Group 3=601pg/mL≤PTH. The study was approved by the Local ethics committee and all patients provided written informed consent. All participants underwent detailed clinical examination. Demographic information and medical history of patients were obtained at baseline by interview with patients and review of medical records.

Blood sampling and assay methods {#sec2-2}
--------------------------------

Blood samples were taken after an overnight fast at between 8:00 and 9:00 am before HD session. At the end of HD session, blood pump speed was reduced to \<80 mL/min and blood samples was obtained at 2 minutes post dialysis from arterial dialysis tubing for calculation of adequacy of dialysis using (K~urea~ × Td) / V~urea~ for urea measurement. Laboratory analysis, including creatinin, serum iron (SI), total iron binding capacity (TIBC), albumin, calcium, phosphorus, alkaline phosphates (ALP), PTH, and hemoglobin (Hb) levels, was conducted using standard laboratory methods in central laboratory on the same day. For blood samples, complete blood count was assessed with Siemens Advia 2120i System (Siemens Healthineers, Erlangen, Germany), and biochemical parameters with Olympus AU 2700 autoanalyzer (Olympus Corp., Tokyo, Japan) using specific kits for devices. Ferritin level was determined with Siemens branded-eligible kits (Siemens Healthineers, Erlangen, Germany). PTH level was analyzed with Siemens Advia Centaur XP Immunoassay System (Siemens Healthineers, Erlangen, Germany) using specific kits. Serum and plasma samples were stored at -20ºC until measurement of NGAL and high sensitivity-C-reactive protein (hs-CRP). NGAL (Catalog No: EK0853) was examined using enzyme-linked immunosorbent assay method (Boster Biological Technology Co., Pleasanton, CA, USA; NGAL sensitivity 510 pg/mL). hs-CRP level was measured with Immulite 2000 instruments using chemiluminescent method (detection range: 0.1--250 mg/L; intra assay precision: coefficient of variation \[CV\]% \<10; inter assay precision: CV% \<10) (Siemens Healthineers, Erlangen, Germany).

Transferrin saturation was calculated using following formula: SI/TIBC x 100.

Kt/V calculation was made online by submitting patient dialysis technique and test results to Hypertension Dialysis and Clinical Nephrology website ([www.hdcn.com](http://www.hdcn.com)).

Statistical analysis {#sec2-3}
--------------------

Statistical analyses were performed using SPSS for Windows, version 16.0 (SPSS Inc., Chicago, IL, USA). Descriptive analyses were presented as mean±SD. Normality of variables was assessed using Kolmogorov-Smirnov test. Kruskal-Wallis test was conducted to compare parameters between groups, and Mann-Whitney U-test was performed to test significance of pairwise differences for multiple comparisons. Pearson correlation analysis was employed to test correlations between NGAL and other variables considered in the study. Linear regression analysis employed Pearson coefficients as appropriate. Multiple regression analysis was used to determine independent factors affecting dependent variable (NGAL). Data were expressed as partial correlation coefficients (b) and p value. The results were considered significant if p value was \<0.05.

RESULTS {#sec1-3}
=======

All clinical and biochemical data are presented in [Table 1](#T1){ref-type="table"}.

###### 

Clinical and biochemical data of patients on hemodialysis

                                 Group 1 (mild) 150\<PTH≤300   Group 2 (moderate) 301≤PTH≤600   Group 3 (severe) 601≤PTH   p
  ------------------------------ ----------------------------- -------------------------------- -------------------------- -------
  Age (years)                    52.21±11.60                   51.33±13.53                      52.60±10.01                NS
  Gender (F/M)                   10/7                          9/12                             13/10                      NS
  DM (%)                         8 (47)                        8 (38)                           9 (39.11)                  NS
  HD duration (months)           28.70±20.87                   27.66±16.06                      29.01±14.23                NS
  Kt/V                           1.35±0.07                     1.34±0.08                        1.35±0.08                  NS
  BMI (kg/m^2^)                  21.58±2.69                    22.73±2.46                       22.62±2.58                 NS
  Neutrophil count (per mm^3^)   6348.26±1174.12               6819.35±1326.12                  7129.42±1425.08            NS
  Hb (g/dL)                      11.71±0.23                    11.13±0.34                       10.50±0.50                 a,b,c
  SI (µd/dL)                     51.15±12.25                   54.48±11.09                      55.34±12.29                NS
  Transferrin saturation (%)     34.94±8.25                    32.23±3.91                       36.38±10.06                NS
  Ferritin (ng/mL)               275.76±57.67                  299.19±77.46                     305.43±75.19               NS
  Ca (mg/dL)                     8.73±0.61                     8.96±0.78                        9.02±1.12                  NS
  P (mg/dL)                      4.28±0.76                     4.31±0.69                        5.12±0.84                  C
  CaxP (mg^2^/dL^2^)             42.19±8.78                    46.91±9.02                       50.79±14.97                NS
  Albumin (g/dL)                 3.89±0.48                     3.64±0.39                        2.88±0.62                  b,c
  ALP (IU/L)                     103.58±25.11                  97.86±31.06                      120.91±50.27               NS
  PTH (pg/mL)                    224.94±45.38                  439.52±85.72                     901.73±146.98              a,b,c
  hs-CRP (ng/mL)                 4620.65±1125.49               5364.24±1866.82                  6763.48±1103.78            b,c
  NGAL (pg/mL)                   2870.29±464.72                3926.24±849.06                   7995.09±771.34             a,b,c

ALP: Alkaline phosphatase; BMI: Body mass index; Ca: Calcium; CaxP: Calcium x phosphorus; DM: Diabetes mellitus; F: Female; Kt/V: K~urea~× Td/V~urea~; M: Male; Hb: Hemoglobin; HD: Hemodialysis; hs-CRP: High-sensitivity C-reactive protein; NGAL: Neutrophil gelatinase-associated lipocalin; NS: Not significant; PTH: Parathyroid hormone; SI: Serum iron. Significant difference (p\<0.05) between groups; a=Group 1:2; b=Group 2:3; c=Group 1:3.

There was no significant difference between groups with respect to age, gender, HD duration, Kt/V, neutrophil count, or body mass index. NGAL level was significantly higher in severe SHPT group (p\<0.05). Hb level was significantly lower in patients with severe SHPT compared with both mild and moderate SHPT patients. Although serum ferritin, calcium-phosphorus (CaxP) product, and ALP levels were higher in patients with severe SHPT, there was no significant difference between these groups. No significant difference was detected between mild and moderate SHPT groups in hs-CRP (p\>0.05). Medical treatments of patients are presented in [Table 2](#T2){ref-type="table"}. There was no relationship between vitamin D treatment, NGAL, and Hb levels.

###### 

Medical treatments of patients

                                  Group 1   Group 2   Group 3   p                    
  ------------------------------- --------- --------- --------- ------- ---- ------- -------
  Phosphate binders                                                                  
   Calcium-based                  10        58.82     11        52.38   11   47.82   NS
   Non-calcium-based              3         17.65     8         38.09   12   52.17   a,b,c
  Vitamin D,oral or intravenous   2         11.76     12        57.14   11   47.82   a,c
  Paricalcitol                    --        --        5         23.81   --   --      NA
  Cinacalcet                      --        --        --        --      3    13.04   NA

NA: Not applicable NS: Not significant. Significant difference (p\<0.05) between groups; a=Group 1:2; b=Group 2:3; c=Group 1:3.

Serum NGAL level was significantly positively correlated with serum PTH (r=0.79; p=0.00) and hs-CRP (r=0.52; p=0.01) levels, and negatively correlated with serum Hb (r=-0.56; p=0.00) level in all HD patients. All variables found to be significantly related to NGAL in univariate analysis were introduced in multivariate model using NGAL as dependent variable. After adjustment for other factors, significance was maintained for correlation between NGAL and serum Hb (b=-0.14; p=0.02) ([Figure 1](#F1){ref-type="fig"}) and PTH (b=0.82; p=0.00) ([Figure 2](#F2){ref-type="fig"}).

![Correlation between serum NGAL and Hb levels.](NCI-4-36-g001){#F1}

![Correlation between serum NGAL and PTH levels.](NCI-4-36-g002){#F2}

DISCUSSION {#sec1-4}
==========

PTH is uremic marker, and patients with SHPT may have higher prevalence of serum inflammatory cytokines and oxidative stress, which are associated with high all-cause and cardiovascular-specific mortality \[[@ref9], [@ref10]\]. Additionally, PTH has been identified as a possible factor in development of acquired immune dysfunction. Increases in intracellular calcium levels potentially lead to increase in cellular adenylate cyclase activity; this has been suggested as mechanism by which PTH influences neutrophils via impaired migration, reduced phagocytic activity, and inhibited granulocyte chemotaxis \[[@ref16], [@ref17]\]. In our study, neutrophil count was not associated with severity of SHPT.

Both serum NGAL and hs-CRP levels were higher in severe SHPT group than mild or moderate SHPT groups in our study, a result that represents increased inflammation in severe SHPT patients. Additionally, correlation between NGAL and hs-CRP observed only in severe SHPT group suggests that inflammation is exacerbated with increase in PTH level. Furthermore, in a previous study, we reported that there was correlation between vascular access type and NGAL \[[@ref18]\]. In the present study, only 3 patients had central venous permanent catheters, so we could comment on relationship between vascular access type and NGAL.

Anemia can lead to decreased quality of life (impairment of cardiac function, cognition, and exercise capacity) and increased mortality in HD patients. SHPT has been recognized as a cause of worsening anemia in normochromic and normocytic pattern. In the current study, we observed inverse association between PTH level and serum Hb concentration. This inverse relationship may be explained by elevated PTH level, which may cause resistance to EPO by increasing bone marrow fibrosis, increase osmotic fragility of red blood cells, leading to shortened lifespan, or inhibit proliferation of erythroid precursors. Several studies have shown important relationships between refractory anemia and higher PTH level in HD patients, as well as improvement in anemia after parathyroidectomy or calcitriol treatment \[[@ref19]--[@ref22]\].

NGAL has recently emerged as an important factor in iron homeostasis and erythrocyte growth regulation that may contribute to anemia when chronically elevated \[[@ref23]\]. Also, previous studies have shown that NGAL levels was higher in HD patients compared with healthy subjects, and high level closely reflected iron status and systemic inflammation in HD patients \[[@ref15], [@ref24], [@ref25]\].

In another study, NGAL level was measured in blood and liver after experimental induction of different types of anemia, such as blood loss and hemolytic anemia. This study showed that NGAL upregulation is not exactly mediated only by increased iron demand occurring in anemia. These results led to hypothesis that increased NGAL production may be defense mechanism against general induced hypoxia and that increased synthesis of NGAL is independent of iron status \[[@ref26]\]. Our study demonstrated that the patients with severe SHPT but without iron deficiency anemia had highest NGAL and lowest Hb levels. Correlation analyses indicated that NGAL positively correlated with PTH level and negatively with Hb level in both severe and moderate SHPT groups. These findings suggested that in case of SHPT, NGAL may correlate with anemia, regardless of iron reserve. Correlation of NGAL with hs-CRP was observed only in severe SHPT group. As we did not include any other inflammation marker in our study, we cannot comment on contribution of inflammation to anemia observed in hyperparathyroid state, and with relatively small sample size of patients, and lack of bone marrow biopsies, constitutes important limitation in this cross-sectional study.

In conclusion, SHPT may contribute to severity of anemia in HD patients. We concluded that even when iron deficiency anemia is excluded in patients with SHPT, there was significant negative correlation between serum NGAL and Hb.
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